Conference Coverage
Conference Coverage
HVPG predicts clinical benefit after sustained virologic response
BOSTON – This provides, for the first time, firm evidence that HVPG can be taken as a surrogate endpoint for studies...
Conference Coverage
Pediatric study characterizes recurrent PSC
BOSTON – Recurrence was significantly associated with younger median age at time of transplant and autoimmune hepatitis.
Conference Coverage
Bezafibrate beats placebo in pruritus of chronic cholestasis: The FITCH trial
BOSTON – PPAR agonist now warrants consideration as first-line treatment for “vexing” clinical issue.
Conference Coverage
Rifabutin-based triple therapy for H. pylori gets high marks
SAN ANTONIO – This is the first new Helicobacter pylori eradication agent to be approved by the Food and Drug Administration in 22 years...
Conference Coverage
Over half of NASH patients have improvement in liver fibrosis after bariatric surgery
BOSTON – Bariatric surgery brought significant weight loss and resolution of multiple metabolic comorbidities.
Conference Coverage
Cilofexor passes phase 2 for primary biliary cholangitis
BOSTON – The nonsteroidal farnesoid X receptor agonist can reduce serum levels of liver biomarkers in patients with...
Conference Coverage
Direct-acting antiviral treatment linked to lower mortality in patients with HCC history
BOSTON – Reduced mortality in HCC patients with complete response apparently driven by achievement of sustained...
Conference Coverage
Short-course DAA therapy may prevent hepatitis transmission in transplant patients
BOSTON – While curing infection post transplant works, prevention would be preferable, investigators say.
Conference Coverage
Study spotlights severe NAFLD in lean patients
BOSTON – Lean patients with nonalcoholic fatty liver disease had almost twice the risk of advanced fibrosis as that of overweight and obese...
Conference Coverage
High doses of FXR agonist tropifexor reduce hepatic fat, serum ALT in patients with NASH
BOSTON – Mild pruritus, minor decreases in LDL cholesterol are notable adverse effects of treatment, similar to others in class.